Skip to main content
Erschienen in:

18.04.2018 | Review

Barrett’s Esophagus and Esophageal Adenocarcinoma: How Common Are They Really?

verfasst von: Aaron P. Thrift

Erschienen in: Digestive Diseases and Sciences | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Since the early 1970s, the incidence of esophageal adenocarcinoma (EA) has increased dramatically in most Western populations while the incidence of esophageal squamous cell carcinoma has decreased. As a result, EA has become the predominant subtype of esophageal cancer in North America and Europe and is an important contributor to overall cancer mortality. Barrett’s esophagus (BE), a metaplastic columnar epithelium of the distal esophagus, is the known precursor lesion for EA. EA and BE occur more frequently in white men over 50 years old, as well as in people with frequent symptoms of gastroesophageal reflux, in smokers, and in people who are obese. Conversely, EA and BE are less common in persons using nonsteroidal anti-inflammatory drugs and in person with Helicobacter pylori infection. The 5-year survival rate for patients with EA, although generally poor, has improved during the past decade, and long-term survival is increasingly possible for patients with early or locally advanced disease. This review combines a synthesis of published studies with an analysis of data from the United States National Cancer Institute’s Surveillance, Epidemiology, and End Results program to discuss the change in incidence of EA and summarize current knowledge of risk factors.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.CrossRefPubMed
2.
3.
Zurück zum Zitat Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–146.CrossRefPubMed Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–146.CrossRefPubMed
4.
Zurück zum Zitat Thrift AP. The epidemic of oesophageal carcinoma: where are we now? Cancer Epidemiol. 2016;41:88–95.CrossRefPubMed Thrift AP. The epidemic of oesophageal carcinoma: where are we now? Cancer Epidemiol. 2016;41:88–95.CrossRefPubMed
5.
Zurück zum Zitat Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol. 2012;23:3155–3162.CrossRefPubMed Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol. 2012;23:3155–3162.CrossRefPubMed
6.
Zurück zum Zitat Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119:1149–1158.CrossRefPubMed Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119:1149–1158.CrossRefPubMed
7.
Zurück zum Zitat Post PN, Siersema PD, Van Dekken H. Rising incidence of clinically evident Barrett’s oesophagus in The Netherlands: a nation-wide registry of pathology reports. Scand J Gastroenterol. 2007;42:17–22.CrossRefPubMed Post PN, Siersema PD, Van Dekken H. Rising incidence of clinically evident Barrett’s oesophagus in The Netherlands: a nation-wide registry of pathology reports. Scand J Gastroenterol. 2007;42:17–22.CrossRefPubMed
8.
Zurück zum Zitat Steyerberg EW, Earle CC, Neville BA, Weeks JC. Racial differences in surgical evaluation, treatment, and outcome of locoregional esophageal cancer: a population-based analysis of elderly patients. J Clin Oncol. 2005;23:510–517.CrossRefPubMed Steyerberg EW, Earle CC, Neville BA, Weeks JC. Racial differences in surgical evaluation, treatment, and outcome of locoregional esophageal cancer: a population-based analysis of elderly patients. J Clin Oncol. 2005;23:510–517.CrossRefPubMed
9.
Zurück zum Zitat Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825–1831.CrossRefPubMed Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825–1831.CrossRefPubMed
10.
Zurück zum Zitat Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61:970–976.CrossRefPubMed Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61:970–976.CrossRefPubMed
11.
Zurück zum Zitat Corley DA, Mehtani K, Quesenberry C, Zhao W, de Boer J, Weiss NS. Impact of endoscopic surveillance on mortality from Barrett’s esophagus-associated esophageal adenocarcinomas. Gastroenterology. 2013;145:312–319.CrossRefPubMedPubMedCentral Corley DA, Mehtani K, Quesenberry C, Zhao W, de Boer J, Weiss NS. Impact of endoscopic surveillance on mortality from Barrett’s esophagus-associated esophageal adenocarcinomas. Gastroenterology. 2013;145:312–319.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat El-Serag HB, Naik AD, Duan Z, et al. Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett’s oesophagus. Gut. 2016;65:1252–1260.CrossRefPubMed El-Serag HB, Naik AD, Duan Z, et al. Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett’s oesophagus. Gut. 2016;65:1252–1260.CrossRefPubMed
13.
Zurück zum Zitat Bhat SK, McManus DT, Coleman HG, et al. Oesophageal adenocarcinoma and prior diagnosis of Barrett’s oesophagus: a population-based study. Gut. 2015;64:20–25.CrossRefPubMed Bhat SK, McManus DT, Coleman HG, et al. Oesophageal adenocarcinoma and prior diagnosis of Barrett’s oesophagus: a population-based study. Gut. 2015;64:20–25.CrossRefPubMed
14.
Zurück zum Zitat Nordenstedt H, El-Serag H. The influence of age, sex, and race on the incidence of esophageal cancer in the United States (1992–2006). Scand J Gastroenterol. 2011;46:597–602.CrossRefPubMed Nordenstedt H, El-Serag H. The influence of age, sex, and race on the incidence of esophageal cancer in the United States (1992–2006). Scand J Gastroenterol. 2011;46:597–602.CrossRefPubMed
15.
Zurück zum Zitat Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977–2005. Br J Cancer. 2009;101:855–859.CrossRefPubMedPubMedCentral Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977–2005. Br J Cancer. 2009;101:855–859.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–831.CrossRefPubMed Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–831.CrossRefPubMed
17.
Zurück zum Zitat Cook MB, Corley DA, Murray LJ, et al. Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: a pooled analysis from the Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON). PLoS ONE. 2014;9:e103508.CrossRefPubMedPubMedCentral Cook MB, Corley DA, Murray LJ, et al. Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: a pooled analysis from the Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON). PLoS ONE. 2014;9:e103508.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Thrift AP, Kramer JR, Qureshi Z, Richardson PA, El-Serag HB. Age at onset of GERD symptoms predicts risk of Barrett’s esophagus. Am J Gastroenterol. 2013;108:915–922.CrossRefPubMedPubMedCentral Thrift AP, Kramer JR, Qureshi Z, Richardson PA, El-Serag HB. Age at onset of GERD symptoms predicts risk of Barrett’s esophagus. Am J Gastroenterol. 2013;108:915–922.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Hoyo C, Cook MB, Kamangar F, et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol. 2012;41:1706–1718.CrossRefPubMedPubMedCentral Hoyo C, Cook MB, Kamangar F, et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol. 2012;41:1706–1718.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Steffen A, Huerta JM, Weiderpass E, et al. General and abdominal obesity and risk of esophageal and gastric adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2015;137:646–657.CrossRefPubMed Steffen A, Huerta JM, Weiderpass E, et al. General and abdominal obesity and risk of esophageal and gastric adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2015;137:646–657.CrossRefPubMed
21.
Zurück zum Zitat Lindkvist B, Johansen D, Stocks T, et al. Metabolic risk factors for esophageal squamous cell carcinoma and adenocarcinoma: a prospective study of 580,000 subjects within the Me-Can project. BMC Cancer. 2014;14:103.CrossRefPubMedPubMedCentral Lindkvist B, Johansen D, Stocks T, et al. Metabolic risk factors for esophageal squamous cell carcinoma and adenocarcinoma: a prospective study of 580,000 subjects within the Me-Can project. BMC Cancer. 2014;14:103.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Cook MB, Freedman ND, Gamborg M, Sorensen TI, Baker JL. Childhood body mass index in relation to future risk of oesophageal adenocarcinoma. Br J Cancer. 2015;112:601–607.CrossRefPubMedPubMedCentral Cook MB, Freedman ND, Gamborg M, Sorensen TI, Baker JL. Childhood body mass index in relation to future risk of oesophageal adenocarcinoma. Br J Cancer. 2015;112:601–607.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Levi Z, Kark JD, Shamiss A, et al. Body mass index and socioeconomic status measured in adolescence, country of origin, and the incidence of gastroesophageal adenocarcinoma in a cohort of 1 million men. Cancer. 2013;119:4086–4093.CrossRefPubMed Levi Z, Kark JD, Shamiss A, et al. Body mass index and socioeconomic status measured in adolescence, country of origin, and the incidence of gastroesophageal adenocarcinoma in a cohort of 1 million men. Cancer. 2013;119:4086–4093.CrossRefPubMed
26.
Zurück zum Zitat Kubo A, Cook MB, Shaheen NJ, et al. Sex-specific associations between body mass index, waist circumference and the risk of Barrett’s oesophagus: a pooled analysis from the international BEACON consortium. Gut. 2013;62:1684–1691.CrossRefPubMed Kubo A, Cook MB, Shaheen NJ, et al. Sex-specific associations between body mass index, waist circumference and the risk of Barrett’s oesophagus: a pooled analysis from the international BEACON consortium. Gut. 2013;62:1684–1691.CrossRefPubMed
27.
Zurück zum Zitat El-Serag HB, Hashmi A, Garcia J, et al. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett’s oesophagus: a case-control study. Gut. 2014;63:220–229.PubMed El-Serag HB, Hashmi A, Garcia J, et al. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett’s oesophagus: a case-control study. Gut. 2014;63:220–229.PubMed
28.
Zurück zum Zitat Kendall BJ, Rubenstein JH, Cook MB, et al. Inverse association between gluteofemoral obesity and risk of Barrett’s esophagus in a pooled analysis. Clin Gastroenterol Hepatol. 2016;14:1412–1419.CrossRefPubMedPubMedCentral Kendall BJ, Rubenstein JH, Cook MB, et al. Inverse association between gluteofemoral obesity and risk of Barrett’s esophagus in a pooled analysis. Clin Gastroenterol Hepatol. 2016;14:1412–1419.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Kendall BJ, Thrift AP. Unravelling the riddle of gastroesophageal reflux disease, obesity and Barrett’s esophagus. Clin Gastroenterol Hepatol. 2015;13:2273–2275.CrossRefPubMed Kendall BJ, Thrift AP. Unravelling the riddle of gastroesophageal reflux disease, obesity and Barrett’s esophagus. Clin Gastroenterol Hepatol. 2015;13:2273–2275.CrossRefPubMed
30.
Zurück zum Zitat Chandar AK, Devanna S, Lu C, et al. Association of serum levels of adipokines and insulin with risk of Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13:2241–2255.CrossRefPubMedPubMedCentral Chandar AK, Devanna S, Lu C, et al. Association of serum levels of adipokines and insulin with risk of Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13:2241–2255.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Kendall BJ, Macdonald GA, Prins JB, O’Brien S, Whiteman DC. Total body fat and the risk of Barrett’s oesophagus—a bioelectrical impedance study. Cancer Epidemiol. 2014;38:266–272.CrossRefPubMedPubMedCentral Kendall BJ, Macdonald GA, Prins JB, O’Brien S, Whiteman DC. Total body fat and the risk of Barrett’s oesophagus—a bioelectrical impedance study. Cancer Epidemiol. 2014;38:266–272.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Thrift AP, Kramer JR, Alsarraj A, El-Serag HB. Fat mass by bioelectrical impedance analysis is not associated with increased risk of Barrett esophagus. J Clin Gastroenterol. 2014;48:218–223.CrossRefPubMedPubMedCentral Thrift AP, Kramer JR, Alsarraj A, El-Serag HB. Fat mass by bioelectrical impedance analysis is not associated with increased risk of Barrett esophagus. J Clin Gastroenterol. 2014;48:218–223.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Cook MB, Kamangar F, Whiteman DC, et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst. 2010;102:1344–1353.CrossRefPubMedPubMedCentral Cook MB, Kamangar F, Whiteman DC, et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst. 2010;102:1344–1353.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Steevens J, Schouten LJ, Goldbohm RA, van den Brandt PA. Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer: a prospective cohort study. Gut. 2010;59:39–48.CrossRefPubMed Steevens J, Schouten LJ, Goldbohm RA, van den Brandt PA. Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer: a prospective cohort study. Gut. 2010;59:39–48.CrossRefPubMed
35.
Zurück zum Zitat Cook MB, Shaheen NJ, Anderson LA, et al. Cigarette smoking increases risk of Barrett’s esophagus: an analysis of the Barrett’s and Esophageal Adenocarcinoma Consortium. Gastroenterology. 2012;142:744–753.CrossRefPubMedPubMedCentral Cook MB, Shaheen NJ, Anderson LA, et al. Cigarette smoking increases risk of Barrett’s esophagus: an analysis of the Barrett’s and Esophageal Adenocarcinoma Consortium. Gastroenterology. 2012;142:744–753.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Smith KJ, O’Brien SM, Green AC, Webb PM, Whiteman DC. Current and past smoking significantly increase risk for Barrett’s esophagus. Clin Gastroenterol Hepatol. 2009;7:840–848.CrossRefPubMed Smith KJ, O’Brien SM, Green AC, Webb PM, Whiteman DC. Current and past smoking significantly increase risk for Barrett’s esophagus. Clin Gastroenterol Hepatol. 2009;7:840–848.CrossRefPubMed
37.
Zurück zum Zitat Edelstein ZR, Farrow DC, Bronner MP, Rosen SN, Vaughan TL. Central adiposity and risk of Barrett’s esophagus. Gastroenterology. 2007;133:403–411.CrossRefPubMed Edelstein ZR, Farrow DC, Bronner MP, Rosen SN, Vaughan TL. Central adiposity and risk of Barrett’s esophagus. Gastroenterology. 2007;133:403–411.CrossRefPubMed
38.
Zurück zum Zitat Anderson LA, Watson RG, Murphy SJ, et al. Risk factors for Barrett’s oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol. 2007;13:1585–1594.CrossRefPubMedPubMedCentral Anderson LA, Watson RG, Murphy SJ, et al. Risk factors for Barrett’s oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol. 2007;13:1585–1594.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Kubo A, Levin TR, Block G, et al. Cigarette smoking and the risk of Barrett’s esophagus. Cancer Causes Control. 2009;20:303–311.CrossRefPubMed Kubo A, Levin TR, Block G, et al. Cigarette smoking and the risk of Barrett’s esophagus. Cancer Causes Control. 2009;20:303–311.CrossRefPubMed
40.
Zurück zum Zitat Thrift AP, Kramer JR, Richardson PA, El-Serag HB. No significant effects of smoking or alcohol consumption on risk of Barrett’s esophagus. Dig Dis Sci. 2014;59:108–116.CrossRefPubMed Thrift AP, Kramer JR, Richardson PA, El-Serag HB. No significant effects of smoking or alcohol consumption on risk of Barrett’s esophagus. Dig Dis Sci. 2014;59:108–116.CrossRefPubMed
41.
Zurück zum Zitat Hardikar S, Onstad L, Blount PL, Odze RD, Reid BJ, Vaughan TL. The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett’s esophagus. PLoS ONE. 2013;8:e52192.CrossRefPubMedPubMedCentral Hardikar S, Onstad L, Blount PL, Odze RD, Reid BJ, Vaughan TL. The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett’s esophagus. PLoS ONE. 2013;8:e52192.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Coleman HG, Bhat S, Johnston BT, McManus D, Gavin AT, Murray LJ. Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett’s esophagus. Gastroenterology. 2012;142:233–240.CrossRefPubMed Coleman HG, Bhat S, Johnston BT, McManus D, Gavin AT, Murray LJ. Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett’s esophagus. Gastroenterology. 2012;142:233–240.CrossRefPubMed
43.
Zurück zum Zitat Ramus JR, Gatenby PA, Caygill CP, Watson A, Winslet MC. The relationship between smoking and severe dysplastic disease in patients with Barrett’s columnar-lined oesophagus. Eur J Cancer Prev. 2012;21:507–510.CrossRefPubMed Ramus JR, Gatenby PA, Caygill CP, Watson A, Winslet MC. The relationship between smoking and severe dysplastic disease in patients with Barrett’s columnar-lined oesophagus. Eur J Cancer Prev. 2012;21:507–510.CrossRefPubMed
44.
Zurück zum Zitat Olsen CM, Pandeya N, Green AC, Webb PM, Whiteman DC. Population attributable fractions of adenocarcinoma of the esophagus and gastroesophageal junction. Am J Epidemiol. 2011;174:582–590.CrossRefPubMed Olsen CM, Pandeya N, Green AC, Webb PM, Whiteman DC. Population attributable fractions of adenocarcinoma of the esophagus and gastroesophageal junction. Am J Epidemiol. 2011;174:582–590.CrossRefPubMed
45.
Zurück zum Zitat Engel LS, Chow WH, Vaughan TL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003;95:1404–1413.CrossRefPubMed Engel LS, Chow WH, Vaughan TL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003;95:1404–1413.CrossRefPubMed
46.
Zurück zum Zitat Hazelton WD, Curtius K, Inadomi JM, et al. The role of gastroesophageal reflux and other factors during progression to esophageal adenocarcinoma. Cancer Epidemiol Biomark Prev. 2015;24:1012–1023.CrossRef Hazelton WD, Curtius K, Inadomi JM, et al. The role of gastroesophageal reflux and other factors during progression to esophageal adenocarcinoma. Cancer Epidemiol Biomark Prev. 2015;24:1012–1023.CrossRef
47.
Zurück zum Zitat Freedman ND, Murray LJ, Kamangar F, et al. Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut. 2011;60:1029–1037.CrossRefPubMedPubMedCentral Freedman ND, Murray LJ, Kamangar F, et al. Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut. 2011;60:1029–1037.CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Thrift AP, Cook MB, Vaughan TL, et al. Alcohol and the risk of Barrett’s esophagus: a pooled analysis from the International BEACON Consortium. Am J Gastroenterol. 2014;109:1586–1594.CrossRefPubMedPubMedCentral Thrift AP, Cook MB, Vaughan TL, et al. Alcohol and the risk of Barrett’s esophagus: a pooled analysis from the International BEACON Consortium. Am J Gastroenterol. 2014;109:1586–1594.CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat Liao LM, Vaughan TL, Corley DA, et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology. 2012;142:442–452.CrossRefPubMed Liao LM, Vaughan TL, Corley DA, et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology. 2012;142:442–452.CrossRefPubMed
50.
Zurück zum Zitat Thrift AP, Anderson LA, Murray LJ, et al. Nonsteroidal anti-inflammatory drug use is not associated with reduced risk of Barrett’s esophagus. Am J Gastroenterol. 2016;111:1528–1535.CrossRefPubMedPubMedCentral Thrift AP, Anderson LA, Murray LJ, et al. Nonsteroidal anti-inflammatory drug use is not associated with reduced risk of Barrett’s esophagus. Am J Gastroenterol. 2016;111:1528–1535.CrossRefPubMedPubMedCentral
51.
Zurück zum Zitat Vaughan TL, Dong LM, Blount PL, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s oesophagus: a prospective study. Lancet Oncol. 2005;6:945–952.CrossRefPubMed Vaughan TL, Dong LM, Blount PL, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s oesophagus: a prospective study. Lancet Oncol. 2005;6:945–952.CrossRefPubMed
52.
Zurück zum Zitat Alexandre L, Clark AB, Bhutta HY, Holt S, Lewis MP, Hart AR. Statin use is associated with reduced risk of histologic subtypes of esophageal cancer: a nested case-control analysis. Gastroenterology. 2014;146:661–668.CrossRefPubMed Alexandre L, Clark AB, Bhutta HY, Holt S, Lewis MP, Hart AR. Statin use is associated with reduced risk of histologic subtypes of esophageal cancer: a nested case-control analysis. Gastroenterology. 2014;146:661–668.CrossRefPubMed
53.
Zurück zum Zitat Beales IL, Vardi I, Dearman L, Broughton T. Statin use is associated with a reduction in the incidence of esophageal adenocarcinoma: a case control study. Dis Esophagus. 2013;26:838–846.CrossRefPubMed Beales IL, Vardi I, Dearman L, Broughton T. Statin use is associated with a reduction in the incidence of esophageal adenocarcinoma: a case control study. Dis Esophagus. 2013;26:838–846.CrossRefPubMed
54.
Zurück zum Zitat Nguyen T, Khalaf N, Ramsey D, El-Serag HB. Statin use is associated with a decreased risk of Barrett’s esophagus. Gastroenterology. 2014;147:314–323.CrossRefPubMed Nguyen T, Khalaf N, Ramsey D, El-Serag HB. Statin use is associated with a decreased risk of Barrett’s esophagus. Gastroenterology. 2014;147:314–323.CrossRefPubMed
55.
Zurück zum Zitat Nguyen T, Duan Z, Naik AD, Kramer JR, El-Serag HB. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett’s esophagus: a nested case-control study. Gastroenterology. 2015;149:1392–1398.CrossRefPubMed Nguyen T, Duan Z, Naik AD, Kramer JR, El-Serag HB. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett’s esophagus: a nested case-control study. Gastroenterology. 2015;149:1392–1398.CrossRefPubMed
56.
Zurück zum Zitat Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis. Gut. 2014;63:1229–1237.CrossRefPubMed Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis. Gut. 2014;63:1229–1237.CrossRefPubMed
57.
Zurück zum Zitat Nie S, Chen T, Yang X, Huai P, Lu M. Association of Helicobacter pylori infection with esophageal adenocarcinoma and squamous cell carcinoma: a meta-analysis. Dis Esophagus. 2014;27:645–653.CrossRefPubMed Nie S, Chen T, Yang X, Huai P, Lu M. Association of Helicobacter pylori infection with esophageal adenocarcinoma and squamous cell carcinoma: a meta-analysis. Dis Esophagus. 2014;27:645–653.CrossRefPubMed
58.
Zurück zum Zitat Fischbach LA, Nordenstedt H, Kramer JR, et al. The association between Barrett’s esophagus and Helicobacter pylori infection: a meta-analysis. Helicobacter. 2012;17:163–175.CrossRefPubMedPubMedCentral Fischbach LA, Nordenstedt H, Kramer JR, et al. The association between Barrett’s esophagus and Helicobacter pylori infection: a meta-analysis. Helicobacter. 2012;17:163–175.CrossRefPubMedPubMedCentral
59.
Zurück zum Zitat Becker J, May A, Gerges C, et al. Supportive evidence for FOXP1, BARX1, and FOXF1 as genetic risk loci for the development of esophageal adenocarcinoma. Cancer Med. 2015;4:1700–1704.CrossRefPubMedPubMedCentral Becker J, May A, Gerges C, et al. Supportive evidence for FOXP1, BARX1, and FOXF1 as genetic risk loci for the development of esophageal adenocarcinoma. Cancer Med. 2015;4:1700–1704.CrossRefPubMedPubMedCentral
60.
Zurück zum Zitat Palles C, Chegwidden L, Li X, et al. Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett’s esophagus. Gastroenterology. 2015;148:367–378.CrossRefPubMedPubMedCentral Palles C, Chegwidden L, Li X, et al. Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett’s esophagus. Gastroenterology. 2015;148:367–378.CrossRefPubMedPubMedCentral
61.
Zurück zum Zitat Levine DM, Ek WE, Zhang R, et al. A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett’s esophagus. Nat Genet. 2013;45:1487–1493.CrossRefPubMedPubMedCentral Levine DM, Ek WE, Zhang R, et al. A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett’s esophagus. Nat Genet. 2013;45:1487–1493.CrossRefPubMedPubMedCentral
62.
Zurück zum Zitat Lee E, Stram DO, Ek WE, et al. Pleiotropic analysis of cancer risk loci on esophageal adenocarcinoma risk. Cancer Epidemiol Biomark Prev. 2015;24:1801–1803.CrossRef Lee E, Stram DO, Ek WE, et al. Pleiotropic analysis of cancer risk loci on esophageal adenocarcinoma risk. Cancer Epidemiol Biomark Prev. 2015;24:1801–1803.CrossRef
63.
Zurück zum Zitat Dong J, Buas MF, Gharahkhani P, Kendall BJ, Onstad L, Zhao S, et al. Determining risk of Barrett’s esophagus and esophageal adenocarcinoma based on epidemiologic factors and genetic variants. Gastroenterology. 2018;154:1273–1281.CrossRefPubMed Dong J, Buas MF, Gharahkhani P, Kendall BJ, Onstad L, Zhao S, et al. Determining risk of Barrett’s esophagus and esophageal adenocarcinoma based on epidemiologic factors and genetic variants. Gastroenterology. 2018;154:1273–1281.CrossRefPubMed
64.
Zurück zum Zitat Thrift AP, Garcia JM, El-Serag HB. A multibiomarker risk score helps predict risk for Barrett’s esophagus. Clin Gastroenterol Hepatol. 2014;12:1267–1271.CrossRefPubMed Thrift AP, Garcia JM, El-Serag HB. A multibiomarker risk score helps predict risk for Barrett’s esophagus. Clin Gastroenterol Hepatol. 2014;12:1267–1271.CrossRefPubMed
65.
Zurück zum Zitat Thrift AP, Kendall BJ, Pandeya N, Vaughan TL, Whiteman DC. A clinical risk prediction model for Barrett esophagus. Cancer Prev Res (Phila). 2012;5:1115–1123.CrossRef Thrift AP, Kendall BJ, Pandeya N, Vaughan TL, Whiteman DC. A clinical risk prediction model for Barrett esophagus. Cancer Prev Res (Phila). 2012;5:1115–1123.CrossRef
66.
Zurück zum Zitat Thrift AP, Kendall BJ, Pandeya N, Whiteman DC. A model to determine absolute risk for esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2013;11:138–144.CrossRefPubMed Thrift AP, Kendall BJ, Pandeya N, Whiteman DC. A model to determine absolute risk for esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2013;11:138–144.CrossRefPubMed
67.
Zurück zum Zitat Thrift AP, Vaughan TL, Anderson LA, Whiteman DC, El-Serag HB. External validation of the Michigan Barrett’s esophagus prediction tool. Clin Gastroenterol Hepatol. 2017;15:1124–1126.CrossRefPubMedPubMedCentral Thrift AP, Vaughan TL, Anderson LA, Whiteman DC, El-Serag HB. External validation of the Michigan Barrett’s esophagus prediction tool. Clin Gastroenterol Hepatol. 2017;15:1124–1126.CrossRefPubMedPubMedCentral
68.
Zurück zum Zitat Thrift AP, Kanwal F, El-Serag HB. Prediction models for gastrointestinal and liver diseases: too many developed, too few validated. Clin Gastroenterol Hepatol. 2016;14:1678–1680.CrossRefPubMed Thrift AP, Kanwal F, El-Serag HB. Prediction models for gastrointestinal and liver diseases: too many developed, too few validated. Clin Gastroenterol Hepatol. 2016;14:1678–1680.CrossRefPubMed
Metadaten
Titel
Barrett’s Esophagus and Esophageal Adenocarcinoma: How Common Are They Really?
verfasst von
Aaron P. Thrift
Publikationsdatum
18.04.2018
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 8/2018
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5068-6

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Risiko für Optikusneuropathie unter Semaglutid in Studie erhöht

In einer retrospektiven Kohortenstudie war das Risiko, eine bestimmte Form von Optikusneuropathie zu entwickeln, bei Diabeteskranken unter Semaglutid erhöht. Das Studiendesign gibt allerdings Anlass zu Zweifeln.

Neuer Score zeigt: Wer profitiert wirklich von der TAVI?

Die Risikoscores, die derzeit zur Indikationsstellung einer TAVI herangezogen werden sollten, sind nicht spezifisch für die TAVI evaluiert worden. Ein neuer Score ist präziser, doch kann er sich in der Praxis durchsetzen?

Neue Impfstoffe und Prophylaxe gegen Influenza, RSV und COVID-19

Die Entwicklung von Impfstoffen und prophylaktischen Medikamenten zur Eindämmung der großen drei akuten respiratorischen Infektionen – COVID-19, RSV und Influenza – steht nicht still. Einen aktuellen Überblick gab es beim DGP-Kongress.

Vergessen Sie nicht Lp(a) zu messen!

Neue Therapien zur Senkung erhöhter Lp(a)-Spiegel sind in der Entwicklung, aber (noch) nicht verfügbar. Dennoch gibt es in der Praxis schon jetzt gute Gründe, bei einem Menschen den Lp(a)-Wert mindestens einmal im Leben zu bestimmen.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.